The patent allows for products containing between 20 and 200mg of the isoflavones that are typically used to mediate menopausal conditions such as rashes and hot flushes as well as premenstrual syndrome.
Frutarom licenses the patent from its Australian holder, Novogen Research.
“Women’s health, and specifically the treatment of menopausal symptoms, is the most common indication for products containing isoflavones,” said David Hart, product manager of Frutarom’s SoyLife.
“We intend to work in cooperation with potential customers to ensure that they can use the positioning covered by the patent. This is a validation of our strategy of investing in and developing Intellectual Property, including patents and scientific studies, to support SoyLife and the isoflavone market.”